TY -的T1 Anti-LGI1-Associated认知障碍:临床资料和长期结果(P6.124) JF -神经学乔-神经学六世- 86 - 16补充SP - P6.124盟-海伦娜Arino AU - Mar Petit首页-Pedrol盟泰国人Armangue AU -阿尔伯特Saiz盟约瑟Dalmau AU -弗朗西斯克格劳Y1 - 2016/04/05 UR - //www.ez-admanager.com/content/86/16_Supplement/P6.124.abstract N2 -背景和目的:LGI1抗体(LGI1-abs)患者症状的范围和长期认知结果是未知的。我们旨在定义这些功能在一个大的病人。设计/方法:信息从病人诊断为LGI-abs综合症相关综述了1998年和2014年之间。使用临床、MRI和CSF标准,症状是归类为边缘脑炎(LE),其它脑炎(OE)和脑病(没有证据表明MRI或脑脊液炎症)。频率或复发,复苏的程度,和LGI1-abs后续评估患者的随访≥18个月。结果:80例患者,7发作没有明确的认知障碍,73有初步认知功能障碍(这份报告的重点)。这73个患者中,有61 (84 [percnt])勒(MRI显示边缘参与,47国),2 OE和10 (14 [percnt])脑病。49 (67 [percnt])≥18个月的随访(中位数,39个月;差21-56)。所有患者接受至少一种类型的免疫抑制剂; 21 (43[percnt]) returned to their pre-morbid cognitive baseline; 11(22[percnt]) became independent for activities of daily living (ADL) but were unable to return to work or at their pre-morbid baseline, 9 (18[percnt]) required ADL assistance and had moderate cognitive impairment, 2 (4[percnt]) had severe cognitive deficits, and 6 (12[percnt]) died, 5 from complications of the disease. Relapses requiring further immunotherapy occurred in 12 patients (24[percnt]). Paired serum/CSF samples were available from 51 patients: 47 (92[percnt]) had LGI1-abs in both and 4 (8[percnt]) only in CSF. Serum LGI1-abs remained detectable in 8/21(38[percnt]) patients after a median follow-up of 19 months (range: 2-188); 5 of them were clinically recovered. Conclusions: Up to 14[percnt] of patients with LGI1-abs have cognitive impairment without MRI or CSF evidence of encephalitis. After immunotherapy only 43[percnt] of all patients return to their baseline cognitive function. Antibodies can remain detectable after full clinical recovery.Disclosure: Dr. Arino has nothing to disclose. Dr. Petit-Pedrol has nothing to disclose. Dr. Armangue has nothing to disclose. Dr. Saiz has received personal compensation for consulting services and speaking from Bayer-Schering, Merck-Serono, Biogen Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis. Dr. Dalmau has received personal compensation in an editorial capacity from the board of Up-To-Date. Dr. Dalmau has received royalty payments from Memorial Sloan-Kettering Cancer Center. Dr. Dalmau has received research support from Euroimmun. Dr. Graus has nothing to disclose.Thursday, April 21 2016, 8:30 am-5:30 pm ER -